Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Fusion Antibodies: Client Projects and Cash Runway Remain in Focus (LSE:FAB)

The immediate question for investors is whether recent business developments can translate into measurable progress. For this company, the principal themes are antibody engineering and discovery services; client-funded projects, laboratory utilisation, contract conversion and cash runway. Investors typically look for evidence in formal company …

Ankur Sharma | 27 October 2026

Healthcare in Focus: The Evidence and Milestones That Matter for Avacta Group plc (LSE:AVCT)

On 27 October 2026, Avacta Group plc (LSE:AVCT) is best assessed through the specific business drivers that can influence its next update, rather than through a broad assumption that every small-cap share is trending for the same reason. Avacta is in focus as investors …

Ankur Sharma | 27 October 2026

Healthcare in Focus: The Evidence and Milestones That Matter for Feedback plc (LSE:FDBK)

On 27 October 2026, Feedback plc (LSE:FDBK) is best assessed through the specific business drivers that can influence its next update, rather than through a broad assumption that every small-cap share is trending for the same reason. Feedback is watched as healthcare providers look …

Ankur Sharma | 27 October 2026

Healthcare in Focus: The Evidence and Milestones That Matter for IXICO plc (LSE:IXI)

On 27 October 2026, IXICO plc (LSE:IXI) is best assessed through the specific business drivers that can influence its next update, rather than through a broad assumption that every small-cap share is trending for the same reason. IXICO is attracting attention as investors assess …

Ankur Sharma | 27 October 2026

Why Did Smith & Nephew Plc LSE:SN Gain 0.18% as London Stocks Moved Lower?

Smith & Nephew Plc — LSE:SN closed 0.18% higher on27 October 2026, with the shares at 1,138.50p after an increase of 2.00p on the day.

Ishan Mudgal | 27 October 2026

Why Did AstraZeneca Plc LSE:AZN Drop 0.09% in a Weaker London Session?

AstraZeneca Plc — LSE:AZN closed 0.09% lower on27 October 2026, with the shares at 12,842.00p after a decline of 12.00p on the day.

Ishan Mudgal | 27 October 2026

Genomics at a Crossroads: Oxford Nanopore (LSE:ONT) Eyes the Road to Breakeven

The central question for investors is how quickly the company can convert growth and cost control into adjusted EBITDA breakeven, which management now targets for FY27.

Divya Sood | 27 October 2026

Vets, Remedies and Australia: Inside the Next Chapter for CVS Group (LSE:CVSG)

The results highlight a group that is growing through acquisitions in Australia and the UK while adapting to a new regulatory framework.

Divya Sood | 27 October 2026

CRISM Therapeutics in Focus: Which Development Milestones Matter Next?

CRISM Therapeutics (CRTX) is in focus on 27 October 2026 as investors assess the latest company-specific developments alongside a shifting UK equity-market backdrop. The stock sits within the AIM, making its performance relevant to investors tracking both the company and its wider market segment. …

Ankur Sharma | 27 October 2026

GSK in Focus: Pipeline Progress and Commercial Execution Under Review

GSK (GSK) is in focus on 27 October 2026 as investors assess the latest company-specific developments alongside a shifting UK equity-market backdrop. The stock sits within the FTSE 100, making its performance relevant to investors tracking both the company and its wider market segment. …

Ankur Sharma | 27 October 2026
Support

Hi! How can we help you today?

Loading…